MedTech faces one more weak quarter before a 2027 rebound

The medical technology sector is entering a new earnings season without illusions. According to Bloomberg Tech, companies face one more subdued quarter, after which the industry will move into 2027 with its strongest growth forecast in more than two years. The previous period was a hard one: policy uncertainty, cyberattacks and device recalls.

The announcement includes no list of companies and no revenue figures, so it is best read as a signal of market sentiment. It gives no exact percentages.

Three factors that weighed on the sector

The first factor is policy. When a manufacturer cannot tell how tariffs, reimbursement rules or regulatory requirements will change, it postpones investment, and its customers postpone purchases. This hits especially hard in equipment with long sales cycles: hospitals do not buy expensive systems when the rules are unclear.

The second factor is cyberattacks. The healthcare industry has long been a target. A telling example is the 2024 attack on Change Healthcare, which disrupted payments across the US healthcare system. Network-connected devices, cloud platforms and software vendors have widened the attack surface. Every incident pushes security spending higher, and customers demand more guarantees from vendors.

The third factor is device recalls. Each one hits several line items at once: direct costs, halted shipments, reputation and regulatory attention. Increasingly, the cause is the product's software rather than its mechanics.

Why 2027 looks better

Bloomberg's logic is simple. The weak quarter is already priced into expectations, and the 2026 baseline remains low. Against that backdrop, even a modest recovery in demand produces noticeable year-over-year growth. To the analysts' credit, they speak of the strongest forecast in over two years, not of a return to pre-crisis levels.

Key parameters of the story:

• near term: one more subdued quarter of earnings;
• next horizon: 2027, with the best growth forecast in 2+ years;
• negative factors: policy uncertainty, cyberattacks, device recalls;
• what the piece does not disclose: specific companies, revenue, margins and the size of the expected growth.

Where AI comes in

The announcement has no direct link to neural networks, but an indirect one is obvious. The FDA's list of AI-enabled medical devices passed a thousand entries some time ago, and most of these products involve image analysis. Such systems are sold as part of large procurement cycles, so weak hospital budgets slow AI adoption too. The reverse also holds: if spending revives in 2027, the first to benefit will be products that are easy to fit into existing infrastructure and that pass cybersecurity review.

This is a hypothesis, not a conclusion drawn from the Bloomberg text. Only earnings reports and management commentary can confirm it.

What to watch in upcoming earnings reports

Investors and anyone working with medical vendors should check a few things:

1. Wording about 2027. If management backs up an acceleration with specific orders, that carries more weight than general statements of optimism. 2. Reserves and cybersecurity costs. Growth in these lines shows how heavy the legacy of the attacks has been. 3. Recall status. It matters whether recalls are closed or still affecting shipments. 4. The share of software and AI features in new products, and how companies describe their validation and data protection.

For now, the market just has to get through one more quiet quarter.